¿ Amylin Pharmaceuticals Inc., of San Diego, began a single-blind, dose-rising, placebo-controlled study of AC2993 (synthetic exendin-4) in Type II diabetics. The study, expected to be completed in the second quarter, will evaluate plasma glucose and insulin concentrations as well as safety and tolerability.

¿ COR Therapeutics Inc., of South San Francisco, and worldwide Integrilin partner, Schering-Plough Corp., of Madison, N.J., said regulatory authorities in Europe recommended approval of the drug for preventing myocardial infarction (MI) in patients with unstable angina or non-Q-wave MI. The action serves as the basis for European Commission approval, which is typically issued in four months and would result in a single marketing authorization valid in all 15 European Union member states.

¿ Coulter Pharmaceutical Inc. is relocating to South San Francisco from Palo Alto, Calif. More than 150 employees will work at the 50,000-square-foot facility.

¿ EntreMed Inc., of Rockville, Md., signed a letter of intent according to which Covance Biotechnology Services Inc., of Research Triangle Park, N.C., will provide large-scale Good Manufacturing Practices production of the Angiostatin protein for further preclinical studies and early human trials.

¿ The Liposome Co., of Princeton, N.J., said Wyeth-Ayerst International, a subsidiary of Madison, N.J.-based American Home Products Corp., will assume marketing responsibilities for Abelcet (lipid-based amphotericin B) in the U.K. Some salespeople from Liposome will join Wyeth-Ayerst¿s organization. Liposome said the move is expected to improve profitability.

¿ Neoprobe Corp., of Dublin, Ohio, completed a $3 million convertible preferred stock private placement with two Aries Funds, of the Cayman Islands. Another $3 million will be available upon completion of several conditions, including shareholder approval. The initial conversion price for the $3 million is $1.03 per share. Warrants were issued to purchase the same amount of shares at the same price.

¿ Ontogeny Inc., of Cambridge, Mass., entered into separate agreements in the area of basal cell carcinoma with the University of California at San Francisco and Brigham and Women¿s Hospital, in conjunction with the Dana-Farber Cancer Institute. Ontogeny and UCSF will evaluate novel compounds. Ontogeny and BWH will try to elucidate molecular pathways involved and identify therapeutic agents.

¿ Roche Molecular Systems Inc., of Branchburg, N.J., received FDA approval to market its Amplicor HIV-1 Monitor UltraSensitive Method, a test to measure viral load in HIV patients. The test can measure levels as low as 50 copies per milliliter of plasma. The test, based on PCR technology, has been available to the research community for a few years.

¿ Zila Inc., of Phoenix, said it was granted a $9 million line of credit by Bank One Corp., of Chicago. It said the terms were more favorable than a previous $2 million credit line with that bank.